Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is the most common inherited genetic change that increases the risk of several
18. Dezember 2024, 6:00 Uhr Lesezeit: 4 Min. Ein Bluttropfen vom Fuß eines Babys genügt, um viele Krankheit zu erkennen. (Archivbild) (Foto: picture alliance /…
Cancer can be tough to explain to kids, but child life specialists can help patients and their families communicate difficult details with care, clarity and…
The diagnostic abilities for assessing prostate cancer patients have significantly evolved in the last years. Ranging from advanced imaging modalities for detection, new innovative liquid…
AbstractIntroduction. Patients with advanced cancer and their spousal caregivers who parent minor children report unmet parenting concerns and increased ps
The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.
Uproleselan plus chemotherapy did not improved overall survival in relapsed/refractory acute myeloid leukemia.
Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
